SNPX Stock Overview
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Synaptogenix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.66 |
| 52 Week High | US$47.00 |
| 52 Week Low | US$3.53 |
| Beta | 1.58 |
| 1 Month Change | -11.66% |
| 3 Month Change | -22.98% |
| 1 Year Change | -81.36% |
| 3 Year Change | -98.11% |
| 5 Year Change | n/a |
| Change since IPO | -94.58% |
Recent News & Updates
Recent updates
We Think Synaptogenix (NASDAQ:SNPX) Can Afford To Drive Business Growth
Sep 20
Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth
May 10Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment
Nov 17Synaptogenix (NASDAQ:SNPX) Is In A Good Position To Deliver On Growth Plans
Oct 05Synaptogenix: The Next Big Thing In Alzheimer's
Jun 16Synaptogenix provides update on phase 2b Alzheimer's disease trial
Jun 09We're Keeping An Eye On Synaptogenix's (NASDAQ:SNPX) Cash Burn Rate
Jun 09Shareholder Returns
| SNPX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.4% | -4.7% | -3.7% |
| 1Y | -81.4% | -2.7% | 20.2% |
Return vs Industry: SNPX underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: SNPX underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| SNPX volatility | |
|---|---|
| SNPX Average Weekly Movement | 18.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SNPX's share price has been volatile over the past 3 months.
Volatility Over Time: SNPX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 5 | Alan Tuchman | www.synaptogen.com |
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
Synaptogenix, Inc. Fundamentals Summary
| SNPX fundamental statistics | |
|---|---|
| Market cap | US$5.06m |
| Earnings (TTM) | -US$13.78m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs SNPX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNPX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.78m |
| Earnings | -US$13.78m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.70 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SNPX perform over the long term?
See historical performance and comparison